Strides Pharma Science balance sheet

As of Sep 2026

Total assets: ₹7,489cr+14.8% on Sep 2025
Shareholders' equity: ₹3,470cr+23.8% on Sep 2025
Total debt: ₹1,847cr+5.6% on Sep 2025
Cash and investments: ₹137cr−33.9% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	958	992	881	879	1,324
	226	161	99.6	79.9	48.3
	0.2	0.2	11.2	11.9	12.6
	601	594	547	529	514
	535	513	461	445	460
	312	286	107	82.0	103
	58.3	12.5	10.7	189	386
	288	279	329	7.6	53.0
	0.0	0.0	0.0	50.0	0.0
	473	475	167	192	40.9
	761	754	496	249	93.9
	284	284	269	267	265
	—	—	68.1	138	188
	3,452	3,314	2,950	2,871	3,395
	1,873	1,635	1,278	1,126	1,147
	0.0	0.0	69.5	106	50.8
	1,464	1,289	1,203	1,142	1,299
	137	189	113	161	304
	10.1	24.4	24.2	30.1	12.5
	8.0	8.1	10.4	12.7	7.8
	544	468	174	120	91.8
	2,164	1,978	1,594	1,571	1,766
	271	271	227	272	223
	4,037	3,613	3,099	2,969	3,135
	0.0	0.5	0.0	0.0	108
	7,489	6,927	6,049	5,840	6,638
Equity
	92.2	92.2	92.2	91.9	90.3
	3,324	3,015	2,460	2,034	2,122
	3,416	3,108	2,552	2,126	2,212
	54.0	41.8	34.6	−53.9	−39.4
	3,470	3,149	2,586	2,072	2,173
Liabilities
	566	552	571	671	1,140
	66.7	83.1	66.2	85.3	216
	633	635	637	757	1,356
	115	126	114	91.6	73.4
	135	121	119	40.3	44.6
	—	—	0.0	0.0	1.8
	883	882	871	889	1,475
	1,281	1,116	1,224	1,743	1,635
	1,433	1,310	1,032	852	982
	156	250	139	104	148
	2,870	2,676	2,396	2,698	2,765
	95.1	96.4	81.2	71.5	122
	31.8	48.4	34.0	40.4	26.7
	138	75.0	80.1	68.9	76.5
	3,135	2,895	2,592	2,879	2,990
	4,018	3,778	3,462	3,768	4,466
	7,489	6,927	6,049	5,840	6,638
Trade payables — MSME split
	87.1	46.4	31.9	—	—
	1,346	1,263	1,001	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,097.50

Strides Pharma Science Ltd.

· Pharma & Health

₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹10,116 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	1,324.3	878.7	880.7	992.4	958.2
+ Capital Work-in-Progress	48.3	79.9	99.6	161.1	226.3
+ Investment Property	12.6	11.9	11.2	0.2	0.2
+ Goodwill	513.8	529.4	546.6	594.4	600.7
+ Other Intangibles	460.4	445.1	460.9	513.5	535.0
+ Intangibles under Development	102.7	82.0	107.1	286.2	311.9
+ Investments (Equity Method)	385.9	189.3	10.7	12.5	58.3
+ Non-current Investments	53.0	7.6	329.0	278.9	287.8
+ Long-term Loans	0.0	50.0	0.0	0.0	0.0
+ Other Non-current Financial Assets	40.9	191.7	166.8	474.7	473.3
Non-current Financial Assets	93.9	249.3	495.8	753.5	761.1
+ Deferred Tax Assets	265.0	267.3	269.1	283.9	283.9
+ Other Non-current Assets	188.2	137.8	68.1	—	—
Total Non-current Assets	3,395.1	2,870.8	2,949.8	3,313.9	3,451.7
Current Assets
+ Inventories	1,146.5	1,126.2	1,277.6	1,634.8	1,873.5
+ Current Investments	50.8	105.8	69.5	0.0	0.0
+ Trade Receivables	1,299.4	1,141.9	1,202.9	1,289.0	1,464.0
+ Cash & Cash Equivalents	303.5	161.0	112.6	188.7	137.3
+ Other Bank Balances	12.5	30.1	24.2	24.4	10.1
+ Short-term Loans	7.8	12.7	10.4	8.1	8.0
+ Other Current Financial Assets	91.8	119.5	174.3	467.8	544.3
Current Financial Assets	1,765.8	1,571.0	1,594.0	1,978.0	2,163.7
+ Other Current Assets	223.0	271.7	227.4	270.5	270.5
Total Current Assets	3,135.3	2,969.0	3,098.9	3,612.8	4,037.2
+ Assets Held for Sale	108.1	0.0	0.0	0.5	0.0
Total Assets	6,638.4	5,839.8	6,048.7	6,927.2	7,488.8
Equity
+ Equity Share Capital	90.3	91.9	92.2	92.2	92.2
+ Other Equity / Reserves	2,122.0	2,033.7	2,459.7	3,015.4	3,324.3
Equity — Owners of Parent	2,212.3	2,125.6	2,551.8	3,107.6	3,416.5
+ Minority Interest	-39.4	-53.9	34.6	41.8	54.0
Total Equity	2,172.9	2,071.7	2,586.5	3,149.3	3,470.5
Liabilities
+ Borrowings — Non-current	1,139.8	671.5	571.2	552.3	566.0
+ Other Non-current Financial Liab	215.7	85.3	66.2	83.1	66.7
Non-current Financial Liabilities	1,355.5	756.8	637.4	635.4	632.7
+ Provisions — Non-current	73.4	91.6	113.9	126.4	115.4
+ Deferred Tax Liabilities	44.6	40.3	119.4	120.7	135.3
+ Other Non-current Liabilities	1.8	0.0	0.0	—	—
Non-current Liabilities	1,475.3	888.8	870.7	882.4	883.3
+ Borrowings — Current	1,634.7	1,743.0	1,224.4	1,116.4	1,281.1
+ Trade Payables	982.3	851.6	1,032.5	1,309.7	1,432.7
+ Other Current Financial Liab	147.5	103.8	139.3	249.7	156.0
Current Financial Liabilities	2,764.5	2,698.4	2,396.2	2,675.8	2,869.9
+ Provisions — Current	122.5	71.5	81.2	96.4	95.1
+ Current Tax Liabilities	26.7	40.4	34.0	48.4	31.8
+ Other Current Liabilities	76.5	68.9	80.1	75.0	138.2
Current Liabilities	2,990.2	2,879.3	2,591.5	2,895.5	3,135.0
Total Liabilities	4,465.5	3,768.0	3,462.3	3,777.9	4,018.3
Total Equity & Liabilities	6,638.4	5,839.8	6,048.7	6,927.2	7,488.8
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	31.9	46.4	87.1
+ Dues to Other Creditors — Current	—	—	1,000.6	1,263.3	1,345.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.